Kura Oncology reports Q4 net loss $19.2M; KOMET-001 trial hits primary endpoint; NDA plan Q2 2025

Kura Oncology, Inc.

2024-FY EPS reported -$2.02 revenue$53,883,000

Q4 collaboration revenue $53.9M (from Kyowa Kirin), R&D $52.3M, net loss $19.2M vs $42.8M YoY.
KOMET-001 achieved primary endpoint with 20-30% CR/CRh rate in R/R NPM1-mutant AML; NDA submission expected Q2 2025.
FDA and EMA aligned on KOMET-017 Phase 3 protocol using MRD-negative CR for potential accelerated U.S. approval; topline 2028.
Cash, equivalents and short-term investments $727.4M as of Dec 31, 2024; sufficient into 2027 with Kyowa funding.
KOMET-007 Phase 1: 91% CR in 1L adverse-risk AML cohort with intensive chemo (7+3) combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.